Viking Global Investors LP Zentalis Pharmaceuticals, Inc. Transaction History

Viking Global Investors LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$41.58 - $80.89 $3.81 Million - $7.41 Million	-91,628 Reduced 4.33%	2,026,656 $93.5 Million
Q3 2021 Nov 15, 2021	SELL	$46.83 - $73.5 $13.2 Million - $20.7 Million	-281,000 Reduced 11.71%	2,118,284 $141 Million
Q1 2021 May 17, 2021	SELL	$35.69 - $52.72 $21.8 Million - $32.3 Million	-612,000 Reduced 20.32%	2,399,284 $104 Million
Q4 2020 Feb 16, 2021	SELL	$31.71 - $57.97 $45.4 Million - $83 Million	-1,432,000 Reduced 32.23%	3,011,284 $156 Million
Q2 2020 Aug 07, 2020	BUY	$23.2 - $54.8 $103 Million - $243 Million	4,443,284 New	4,443,284 $213 Million

139

67.9M

48.5K

89.6K

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $99.2M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

Get notified when there are updates to the investment portfolio of Viking Global Investors LP, based on Form 13F filings with the SEC.

Stay updated on Viking Global Investors LP with notifications on news.